Eamonn Hobbs is the founder of Syncromune. Syncromune has raised $100M in total funding. Latest round: Series A. Backed by TWWG Global.
Eamonn Hobbs is the Founder, President, and CEO of Syncromune, a clinical-stage biopharmaceutical company developing personalized medicine for metastatic solid tumor cancers. He has spent four decades working on the interface between advanced diagnostic and therapeutic products and patient delivery technology. Under his leadership, Syncromune raised one of the few $100M Series A rounds in 2024 and released positive Phase 1 data for its SYNC-T therapy in metastatic prostate cancer at ASCO 2025.
Full founder directory · Investor directory · Company funding database · Fundraising library